SCHEMBL657216

SCHEMBL657216

Cc1nc2ccncn2c1-c1ccnc(C2(c3ccc(C(=O)NO)cc3)CC2)n1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 6/20 0.37
CCNE1 P24864 4/20 0.37
CDK4 P11802 4/20 0.37
HDAC1 Q13547 11/20 0.36
HDAC6 Q9UBN7 4/20 0.35
AKT1 P31749 1/20 0.33
AKT2 P31751 1/20 0.33
MAP3K14 Q99558 1/20 0.33
HDAC3 O15379 2/20 0.33
HDAC2 Q92769 2/20 0.33
HDAC8 Q9BY41 2/20 0.33
JAK2 O60674 1/20 0.33
NCOR1 O75376 1/20 0.33
JAK1 P23458 1/20 0.33
TYK2 P29597 1/20 0.33
JAK3 P52333 1/20 0.33
ACHE P22303 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC9 Q9UKV0 1/20 0.32
HDAC5 Q9UQL6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL658310 0.89 CDK2 (0.37) CDK2CCNE1CDK4HDAC1HDAC6
SCHEMBL3348358 0.87 CDK2 (0.52) CDK2CCNE1CDK4HDAC1
SCHEMBL655847 0.86 HDAC1 (0.49) CDK2CCNE1CDK4HDAC1HDAC6
SCHEMBL3358836 0.85 MAP3K14 (0.50) CDK2CCNE1CDK4HDAC1HDAC6
SCHEMBL655677 0.84 CCNE1 (0.33) CDK2CCNE1CDK4HDAC1HDAC6
SCHEMBL658497 0.84 CDK4 (0.36) CDK2CCNE1CDK4HDAC1HDAC6
SCHEMBL659399 0.84 CCNE1 (0.33) CDK2CCNE1CDK4HDAC1HDAC6
SCHEMBL658247 0.84 HDAC1 (0.39) CDK2CCNE1CDK4HDAC1HDAC6
SCHEMBL657703 0.84 HDAC1 (0.39) CDK2CCNE1CDK4HDAC1HDAC6
SCHEMBL657967 0.83 AKT1 (0.42) CDK2CCNE1CDK4HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. (US) 2012-02-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120045412-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 CDK2 213/4885CCNE1 1992/4885CDK4 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.